BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 18982746)

  • 41. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
    Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
    Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 43. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vimentin and alpha-fetoprotein expression in breast cancer smears: relationship with various prognostic factors.
    Athanassiadou P; Lazaris D; Athanassiades P; Kyrkou K; Petrakakou E; Keramopoulos K; Aravantinos D
    Cancer Detect Prev; 1997; 21(3):207-12. PubMed ID: 9167037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
    Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB
    Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women.
    Singhai R; Patil V; Patil A
    Int J Appl Basic Med Res; 2011 Jan; 1(1):15-9. PubMed ID: 23776766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of a simplified molecular classification of tumors for predicting survival of patients with invasive ductal breast carcinoma.
    Muñoz-Díaz MM; Fernández-Aceñero MJ; Salvadores P; Schneider J
    Anticancer Res; 2009 Nov; 29(11):4727-30. PubMed ID: 20032426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
    Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
    Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proliferation measurement in breast cancer by two different methods.
    Martínez-Arribas F; Martín-Garabato E; Lafuente P; Tejerina A; Lucas R; Sánchez J; Schneider J
    Anticancer Res; 2006; 26(1A):199-202. PubMed ID: 16475699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
    Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
    Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study.
    Bacchi LM; Corpa M; Santos PP; Bacchi CE; Carvalho FM
    Breast; 2010 Apr; 19(2):137-41. PubMed ID: 20117934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
    González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
    Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
    Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
    Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas.
    Leighton X; Srikantan V; Pollard HB; Sukumar S; Srivastava M
    Cancer Lett; 2004 Jul; 210(2):239-44. PubMed ID: 15183540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.